ORIC Pharmaceuticals, Inc.NASDAQ: ORIC

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

· Issued by ORIC Pharmaceuticals, Inc. via GlobeNewswire

Summary by 6ix AI

ORIC Pharmaceuticals, a clinical stage cancer drug developer, said its management will hold fireside chats and one-on-one meetings at three investor conferences on November 10, 11 and 18, 2026.

Key details

  • Guggenheim's 3rd Annual Healthcare Innovation Conference: fireside chat on Tuesday, November 10, 2026, at 10:30 a.m. ET.
  • Stifel 2026 Healthcare Conference: fireside chat on Wednesday, November 11, 2026, at 2:00 p.m. ET.
  • Jefferies London Healthcare Conference: fireside chat on Wednesday, November 18, 2026, at 12:30 p.m. GMT.
  • Webcasts of the fireside chats will be available in the investor section of the company's website, with replays available for 90 days after each event.

6ix AI wrote this summary from the release below and checked it against the release.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November:

  • Guggenheim’s 3rd Annual Healthcare Innovation Conference – Participating in a fireside chat on Tuesday, November 10, 2026, at 10:30 a.m. ET. Management will also be participating in one-on-one meetings.
  • Stifel 2026 Healthcare Conference – Participating in a fireside chat on Wednesday, November 11, 2026, at 2:00 p.m. ET. Management will also be participating in one-on-one meetings.
  • Jefferies London Healthcare Conference – Participating in a fireside chat on Wednesday, November 18, 2026, at 12:30 p.m. GMT. Management will also be participating in one-on-one meetings.

Webcasts of the fireside chat discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:

Dominic Piscitelli, Chief Financial Officer
[email protected]
[email protected]

View original source (GlobeNewswire)ORIC Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from ORIC Pharmaceuticals

Later from ORIC Pharmaceuticals

All ORIC Pharmaceuticals news releases